Karmanos Now Offers FDA-Approved Daraxonrasib (Rasonque) for Metastatic Pancreatic Cancer
RegulatoryapprovedRasonquePositive
AI Analysis
Summary
The Barbara Ann Karmanos Cancer Institute is now offering daraxonrasib (Rasonque), an FDA-approved treatment for metastatic pancreatic cancer, following positive results from the RASolute 302 clinical trial.
Clinical Trial Data
Outcome Details
FDA-approved for metastatic pancreatic cancer
Importance:8/10
Sentiment:
0.80
FDA approvalpancreatic cancerdaraxonrasibRasonqueRASolute 302 trial
Related Companies
Read the original article
Published by PR Newswire Biotech on August 31, 2026 10:05 AM